SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Given that SGLT-2 inhibitors have documented relevant cardio-renal benefits in large RCTs enrolling patients with and without T2DM [103,104], they are attractive agents for patients with NAFLD.